EP3596215A1 - Procédé d'enrichissement de cellules à partir d'un échantillon et d'isolement consécutif de l'acide nucléique de ces cellules - Google Patents

Procédé d'enrichissement de cellules à partir d'un échantillon et d'isolement consécutif de l'acide nucléique de ces cellules

Info

Publication number
EP3596215A1
EP3596215A1 EP18716517.0A EP18716517A EP3596215A1 EP 3596215 A1 EP3596215 A1 EP 3596215A1 EP 18716517 A EP18716517 A EP 18716517A EP 3596215 A1 EP3596215 A1 EP 3596215A1
Authority
EP
European Patent Office
Prior art keywords
cells
sample
nucleic acid
nucleic acids
solid phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18716517.0A
Other languages
German (de)
English (en)
Inventor
Timo Hillebrand
Monique BRENDEL
Kristin WESSEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AJ Innuscreen GmbH
Original Assignee
AJ Innuscreen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AJ Innuscreen GmbH filed Critical AJ Innuscreen GmbH
Publication of EP3596215A1 publication Critical patent/EP3596215A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity

Definitions

  • the invention relates to a novel and highly simplified method which allows to enrich biological cells from a sample and to remove from the sample, then release the nucleic acids contained in the cells and isolate the way that the same means, which was used for the accumulation of cells, is also used for the isolation of nucleic acids.
  • the method can be carried out manually or fully automated. In particular, it simplifies the isolation of nucleic acids from larger sample volumes and in this context also reduces the use of necessary ones
  • nucleic acid-containing starting materials under strongly denaturing and reducing conditions, partially using protein-degrading enzymes, digested and purified the exiting nucleic acid fractions via phenol / chloroform extraction steps and the nucleic acids by means of
  • the "new" methods are based on a method developed and first described by Vogelstein and Gillespie (Proc Natl Acad., USA, 1979, 76, 615-619) for the preparative and analytical purification of DNA fragments from agarose gels combines the dissolution of an agarose containing the DNA band to be isolated in a saturated solution of a chaotropic Salt (NaJ) with a binding of the DNA to glass particles.
  • the DNA fixed to the glass particles is then washed with a washing solution (20 mM Tris HCl [pH 7.2], 200 mM NaCl, 2 mM EDTA, 50% v / v ethanol) and then removed from the carrier particles.
  • This method has undergone a number of modifications to date and is currently used for different methods of extracting and purifying nucleic acids of various origins (Marko, MA, Chipperfield, R. and Birnboim, HG, 1982, Anal. Biochem. 121, 382-387).
  • kits are based on the well-known principle of binding nucleic acids to mineral carriers in the presence of solutions of different chaotropic salts and use as carrier materials
  • Finely ground glass powder e.g., Glasmilk, BIO 101, La Jolla, CA
  • Diatomaceous earth (Sigma) or silica gel. (Diagen, DE 41 39 664 AI).
  • the method is well suited for isolating nucleic acids from small sample quantities and finds its practical application especially in the field of isolation of viral nucleic acids.
  • nucleic acids to solid support materials, especially mineral support materials based on silicon or even to magnetic or paramagnetic silicate support materials or magnetic or paramagnetic materials that carry functional groups, the same function as silicate materials, to bind, to subsequently wash and to detach the nucleic acids from the substrate again.
  • the materials are as membranes (resp.
  • Binding mediation of the nucleic acids to the carrier materials are both so-called.
  • chaotropic salts as well as so-called.
  • a solution variant for the isolation of DNA from larger amounts of blood (> 200 ⁇ ) based on the fact that the sample is mixed in the usual way with a larger volume of lysis buffer, subsequently adding a binding buffer and the approach, for example by means of a "funnel device" successively via a filter membrane for connecting the
  • Nucleic acid passes. Such commercially available kits allow the use of more than 1 ml samples for the isolation of nucleic acid. However, these processes require a significantly higher proportion of extraction reagents and are expensive to carry out.
  • Viral antigen in urine samples In this case, 1.5 ml of sample can be used.
  • the method uses magnetic beads which are coupled to a protein (ApoH). These beads serve to bind virus antigen from the sample. Incubation of sample with beads is 2h. Thereafter, the beads are separated and washed several times. Subsequently, the lysis of the virus is carried out by means of a lysis buffer. The lysis buffer is then placed on a filter column and the nucleic acid bound in a conventional manner to the filter column, washed and subsequently isolated the viral nucleic acid. This process is again expensive and expensive to work with.
  • cells from a sample bind to a solid phase.
  • This solid phase is provided with a nonspecific capture ligand.
  • This coating consists of carbohydrates or carbohydrate derivatives. Preferably, microorganisms bind.
  • the solid phase is magnetic particles. After binding, the solid phase is removed from the sample and the cells are lysed.
  • Nucleic acids or extraction chemistry used for the isolation of the nucleic acids corresponds exactly to the state of the art.
  • these methods are an improvement, since the particles used for cell binding in a further function also allows the isolation of nucleic acids of the bound and separated cells.
  • the disadvantage is the use of magnetic particles. Since they are all nano- or microparticles, the separation of these particles is difficult and very time-consuming, especially with viscous samples.
  • the present invention solves the problem of the combined accumulation of cells and subsequent isolation of the nucleic acids in a surprisingly simple manner.
  • the invention was based on the following surprising observation.
  • a sample containing cells e.g., a blood sample
  • a plastic material having a rough surface e.g., roughened polypropylene
  • the cells bind to the plastic material.
  • rough surface should be understood to mean that it is not smooth by touching or by viewing the surface, but it may also be a surface having a structure (eg grooves).
  • This structure eliminates the smoothness of the surface, even though the structure, ie, the grooves, itself may be smooth, and according to the invention such surfaces are referred to as "structured surfaces". If, by viewing or touching the surface, it is not possible to detect whether a surface is smooth or rough, a test may be performed by directing a laser beam at that surface. With a smooth surface, the laser is only in
  • the cells After fixation of the cells to the surface, the cells can be removed with the surface of the sample.
  • the object of the invention the isolation of the nucleic acids contained in the fixed cells using the same agent, is achieved by lysing the cells with a lysis buffer and thus releases the nucleic acids.
  • nucleic acids these can also be isolated with the same surface, which was used for the fixation of the cells.
  • the inventive method combines for the first time the adsorption of cells of a sample to a material with a "structured surface" with the
  • the process can be carried out as a “single-tube process” or in the form of an automated “walk-away process”. The used
  • Carrier material with a "structured surface” is inexpensive and, in contrast to used nanoparticles, harmless.
  • the process sequence is simple, extremely fast and extremely efficient and combines according to the invention an accumulation of cells with the subsequent extraction of the nucleic acid.
  • the invention relates to the disclosed methods and means of the publications DE 10 2015 216 558, DE 10 2015 211 394 and DE 10 2015 211 393.
  • the invention is based on the properties described therein, that nucleic acids on rough or
  • the present invention shows that such a material is not only suitable for isolating nucleic acids, but also suitable for binding cells from a sample, thus resulting in the method according to the invention of such a material in one Dual function combined to use.
  • the essence of the invention is thus that cells of a sample to a "Structured surface” adsorb and subsequently the liberated nucleic acids are in an aqueous environment whose polarity is adjusted by organic substances so that the solubility of the nucleic acid is reduced and subsequently precipitated on the "structured surface” and subsequently the precipitated DNA of the "structured” gray surface is replaced again and is available.
  • the precipitated on the rough surface nucleic acid can also be washed and replaced after washing steps.
  • This lysis buffer may contain chaotropic salts or non-chaotropic salts or mixtures of these two groups.
  • this buffer may contain other components such as chelating agents, Tris buffer, wetting and dispersing agents, etc.
  • the method also works with buffers which contain no salts and e.g. consist only of a detergent, Tris and EDTA.
  • proteolytic enzymes can also be used.
  • nucleic acid of the sample precipitates to the same structured one
  • the agent according to the invention can also be in a device for extracting nucleic acids, comprising a hollow body through which a liquid is passed, wherein in this hollow body a material with rough
  • a pipette tip acts as a hollow body
  • the rough or "textured surface” material has a size such that it can not escape from the pipette tip at the bottom can and thus differs from the magnetic particles described in the prior art (WO 01/05510 Al).
  • the used in the pipette tip materials for cell adsorption and subsequent attachment of nucleic acids can be extremely different. It can be used modified plastic materials whose surface is not smooth, but rough or textured. These include so-called composite materials containing blends of polymers and e.g. organic components as well as inorganic components. Essential is only the provision of a roughened or
  • “Structured surface” (no smooth surface) or the transfer of material into the pipette tip, which leads to the formation of a two / three-dimensional network, whereby the nucleic acids then precipitate on this structure.
  • the architecture of the material is also not limiting (round, rectangular , etc.), which can also be multiple materials (eg several granules).
  • a pipette tip can be used, in which (made of a molded injection molded part) that binding material is already and this no longer needs to be spent in the top. Also advantageous is the use of rough or structured material, which additionally has magnetic or paramagnetic properties. Such a material is then also suitable for manual sample processing in which it is added separately to the sample and is not located in a hollow body.
  • the sample with the contained cells is "pipetted" by means of pipetting operations on the material according to the invention introduced into the pipette tip, the cells adsorb onto the material
  • calcium chloride may also be added to the sample containing the cells After cell attachment, the pipette tip is immersed in a cavity containing a lysis buffer and possibly also a proteolytic enzyme, lysis of the cells and release of the nucleic acids. The cells are thus no longer on
  • the conditions necessary for the precipitation of the nucleic acids are set so that the nucleic acid can precipitate on the material that is being dispensed in the pipette tips.
  • the approach is by means of pipetting vertically in the
  • wash buffer may optionally be "pipetted” past the nucleic acid binding material, followed by a drying step (e.g., frequent pipetting up and down) Finally, the eluent is again “pipetted” past the vertically arranged nucleic acid binding material, thereby peeling off the bound nucleic acid.
  • the nucleic acid is now available for necessary downstream application. The process is extremely fast and easy to carry out and allows isolation of nucleic acids in extremely high yield and purity.
  • the present invention in addition to the simplicity of the implementation of another enormous advantage. Contains a biological sample large amounts of cells containing nucleic acids, so by means of the method according to the invention and the
  • Materials of the invention are extracted an extremely large amount of nucleic acids.
  • the method is also ideally suited for the processing of large sample volumes.
  • Example 1 Enrichment of cells from an aqueous solution combined with the subsequent extraction of the nucleic acid contained in the cells using a modified pipette tip and using a commercially available extraction machine
  • the automated extraction was carried out with the InnuPure C16 extraction machine (Analytik Jena AG).
  • the pipette tips were changed so that they correspond to the agent according to the invention.
  • a roughened plastic granulate (4 granules with a diameter of about 2 mm - 4 mm, polypropylene) was loosely placed in the lower third of the pipette tips. The granules do not close the lumen of the pipette tip. This preserves the pipetting function of the pipette tips.
  • the reagents required for the procedure were in a pre-filled deep well plate. In the first well of the deep well plate, the aqueous cell suspension was spent.
  • the pipette tip with the material according to the invention was retracted into the cavity.
  • the cell binding is done by pipetting up and down (100 repetitions).
  • the cells adsorb to the material of the invention contained in the tip.
  • the tip was moved out of the cavity.
  • the cells are located on the material inside the tip.
  • the tip was subsequently retracted into a second well of the deep well plate.
  • This cavity contains a commercially available lysis buffer as well as Proteinase K (Lysis Solution CBV, InnuPREP Blood DNA K PC16, Analytik Jena AG).
  • the lysis of the cells located on the material was carried out by pipetting up and down the lysis buffer (200
  • the cavity was additionally heated. At the end of the process, the released nucleic acid of the cells is in the lysis buffer. The cells are no longer on the material according to the invention.
  • the sample was now drawn into the pipette tip and dispensed into another cavity of the deep well plate. This cavity is prefilled with an alcohol (isopropanol). This solution was then again pipetted up and down by means of the pipette tip. Again, so that the solution flows past the granules (100
  • the tip of the invention and the granules contained in it were dried by pipetting air and thus the residual ethanol removed.
  • the elution of the nucleic acids from the granules was carried out in another well of the deep well plate, in which 200 ⁇ water were contained as eluent.
  • the nucleic acid was removed from the granules by pipetting up and down the water (120
  • the method is extremely simple and fast and shows that commercially available extraction machines for carrying out the method according to the invention in the combination of cell binding and removal of cells from the initial sample and subsequent extraction of the nucleic acid contained in the cells with the corresponding inventive Means can be used.
  • the detection of the isolated nucleic acid was carried out by spectrophotometric measurement and gel electrophoresis.
  • FIG. 1 A gel electrophoretic analysis of the isolated nucleic acid is shown in FIG. 1.
  • Example 2 Enrichment of nucleated cells from different volumes of whole blood samples combined with the subsequent extraction of the nucleic acid contained in the nucleated cells using a modified pipette tip and using a commercially available extraction machine
  • the reagents required for the procedure were in a pre-filled deep well plate. Different amounts of blood (200 ⁇ , 300 ⁇ , 400 ⁇ and 500 ⁇ ) were spilled into the first well of the deep well plate. In each case, 800 ⁇ l of a commercially available erythrocyte lysis buffer (Ery Lysis Solution A, Analytik Jena AG) were used for these blood samples. In addition, 200 ⁇ of a 1 M calcium chloride solution was added.
  • the pipette tip with the material according to the invention was retracted into the cavity.
  • the cell binding is done by pipetting up and down (100 repetitions).
  • the nucleated cells adsorb to the material of the invention contained in the tip.
  • the tip was moved out of the cavity.
  • the cells are located on the material inside the tip.
  • the cells were separated from the actual sample and thus also of inhibitory substances such as hemoglobin. This considerably facilitates the subsequent successful extraction of the nucleic acid.
  • the tip was subsequently inserted into a second well of the deep well. Retracted plate.
  • This cavity contains a commercially available lysis buffer as well as Proteinase K (Lysis Solution CBV, InnuPREP Blood DNA K PC16, Analytik Jena AG).
  • the lysis of the cells located on the material was carried out by pipetting up and down the lysis buffer (200 repeats). The cavity was additionally heated. At the end of the process, the released nucleic acid of the cells is in the lysis buffer. The cells are no longer on the material according to the invention.
  • the sample was now drawn into the tip of the beeper and released into another cavity of the deep well plate. This cavity is prefilled with an alcohol (isopropanol).
  • Wash buffer filled. was washed by pipetting up and down the wash buffer (jeticianl 10 repetitions.
  • the tip of the invention and the material contained in it were dried by pipetting air, thereby removing the residual ethanol.
  • the elution of the nucleic acids from the granules was carried out in another well of the deep well plate, in which 200 ⁇ water were contained as eluent.
  • the nucleic acid was removed from the granules by pipetting up and down the water (120
  • the detection of the isolated nucleic acid was carried out by means of spectrophotometric measurement and gel electrophoresis. It turns out that increasing the amount of blood also increases the yield of nucleic acid. Thus, the method is also excellent for the processing of larger sample volumes.
  • FIG. 2 shows a gel electrophoresis analysis of the isolated nucleic acid.
  • the nucleic acid which has been electrophoretically separated in a 0.8% agarose gel and isolated by means of the method according to the invention is shown. The samples were applied from left to right beginning with sample 1. Lane 9 contains a DNA ladder.
  • Example 3 Enrichment of the nucleated cells from whole blood samples combined with the subsequent extraction of the nucleic acid contained in the nucleated cells using three differently modified pipette tips and using a commercially available extraction machine. The automated extraction was again carried out with the InnuPure C16 extraction machine (Analytik Jena AG).
  • pipette tips were changed so that they correspond to the agent according to the invention.
  • pipette tips were modified as follows:
  • Polypropylene (4 granules with a diameter of approx. 2 mm - 4 mm) filled loosely
  • Polypropylene (5 granules with a diameter of approx. 2 mm - 4 mm) loosely filled 3. Pipette tips in the lower third vertically filled with a spiral plastic polyethylene material of a length of 1, 5 cm (as an example of a structured material).
  • the reagents required for the procedure were in a pre-filled deep well plate.
  • a whole blood sample 500 ⁇ was placed in the first well of the deep well plate.
  • 800 ⁇ of a commercially available erythrocyte lysis buffer (Ery Lysis Solution A, Analytik Jena AG) were transferred to this blood sample.
  • 200 ⁇ of a 1 M calcium chloride solution was added.
  • the pipette tip with the material according to the invention was introduced into the cavity.
  • the cell binding is done by pipetting up and down (100 repetitions).
  • the nucleated cells adsorb to the material of the invention contained in the tip.
  • the tip was moved out of the cavity.
  • the cells are located on the material inside the tip.
  • the cells were separated from the actual sample and thus also of inhibitory substances such as hemoglobin. This considerably facilitates the subsequent successful extraction of the nucleic acid.
  • the tip was subsequently retracted into a second well of the deep well plate.
  • This cavity contains a commercially available lysis buffer as well as Proteinase K (Lysis Solution CBV, InnuPREP Blood DNA K PC16, Analytik Jena AG).
  • the lysis of the cells located on the material was carried out by pipetting up and down the lysis buffer (200 repeats). The cavity was additionally heated. At the end of the process, the released nucleic acid of the cells is in the lysis buffer. The cells are no longer on the material according to the invention. The sample was now in the lysis buffer (200 repeats). The cavity was additionally heated. At the end of the process, the released nucleic acid of the cells is in the lysis buffer. The cells are no longer on the material according to the invention. The sample was now in the
  • the tip of the beeper is drawn up and transferred to another cavity of the deep well plate. This cavity is prefilled with an alcohol (isopropanol).
  • the tip of the invention and the material contained in it were dried by pipetting air, thereby removing the residual ethanol.
  • the elution of the nucleic acids from the granules was carried out in another Deep well plate well containing 200 ⁇ of water as eluent.
  • the nucleic acid was detached from the granules by pipetting up and down the water (120 repetitions).
  • the detection of the isolated nucleic acid was carried out by means of spectrophotometric measurement and gel electrophoresis. It turns out that increasing the amount of blood also increases the yield of nucleic acid. Thus, the method is also excellent for the processing of larger sample volumes.
  • FIG. 3 A gel electrophoretic analysis of the isolated nucleic acid is shown in FIG. 3.

Abstract

L'invention concerne l'enrichissement et l'isolement de cellules biologiques à partir d'un échantillon et/ou l'enrichissement de cellules biologiques à partir d'un échantillon et l'isolement consécutif de l'acide nucléique de ces cellules, l'échantillon étant mis en contact avec une phase solide qui présente une surface brute ou structurée.
EP18716517.0A 2017-03-14 2018-03-14 Procédé d'enrichissement de cellules à partir d'un échantillon et d'isolement consécutif de l'acide nucléique de ces cellules Pending EP3596215A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102017204267.2A DE102017204267B4 (de) 2017-03-14 2017-03-14 Verfahren zur anreicherung von zellen aus einer probe und der nachfolgenden nukleinsäureisolierung aus diesen zellen
PCT/EP2018/056371 WO2018167138A1 (fr) 2017-03-14 2018-03-14 Procédé d'enrichissement de cellules à partir d'un échantillon et d'isolement consécutif de l'acide nucléique de ces cellules

Publications (1)

Publication Number Publication Date
EP3596215A1 true EP3596215A1 (fr) 2020-01-22

Family

ID=61913120

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18716517.0A Pending EP3596215A1 (fr) 2017-03-14 2018-03-14 Procédé d'enrichissement de cellules à partir d'un échantillon et d'isolement consécutif de l'acide nucléique de ces cellules

Country Status (5)

Country Link
US (1) US11702648B2 (fr)
EP (1) EP3596215A1 (fr)
CN (1) CN110945124A (fr)
DE (1) DE102017204267B4 (fr)
WO (1) WO2018167138A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023247628A1 (fr) 2022-06-21 2023-12-28 Ist Innuscreen Gmbh Procédé et kit de préparation manuelle et automatisée d'échantillons de séquençages à lecture longue

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019118332B4 (de) * 2019-07-07 2022-04-07 Ist Innuscreen Gmbh Verfahren und testkit zur bisulfitmodifizierung von dna
CN111647596A (zh) * 2020-06-23 2020-09-11 辽宁省海洋水产科学研究院 一种基于3d打印功能体的微孢子虫dna的提取方法、试剂盒及其应用
CN111607489B (zh) * 2020-06-23 2024-04-05 大连理工大学 一种基于3d打印微元件的核酸提取系统和方法
CN111607635B (zh) * 2020-06-23 2024-03-22 大连理工大学 一种基于3d打印特形功能体的血液基因组dna提取方法及其应用试剂盒
CN111778236A (zh) * 2020-06-23 2020-10-16 辽宁省海洋水产科学研究院 基于3d打印特形功能体的贝类基因组dna提取方法、试剂盒及其应用
DE102020135124A1 (de) 2020-12-30 2022-06-30 Aj Innuscreen Gmbh Verfahren und System zur schnellen Isolierung von Nukleinsäuren direkt aus Vollblutproben
DE102021130283B4 (de) * 2021-11-19 2024-03-21 Ist Innuscreen Gmbh Verfahren und testkit zur preiswerten und ressourcensparenden extraktion von nukleinsäuren

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234809A (en) 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
DE4139664A1 (de) 1991-12-02 1993-06-03 Diagen Inst Molekularbio Vorrichtung und verfahren zur isolierung und reinigung von nukleinsaeuren
DE4321904B4 (de) 1993-07-01 2013-05-16 Qiagen Gmbh Verfahren zur chromatographischen Reinigung und Trennung von Nucleinsäuregemischen
JP3761573B2 (ja) 1994-06-14 2006-03-29 インヴィテーク ゲーエムベーハー 極度に少量でかつ非常に強く汚染された非常に種々の出発物質から核酸を単離および精製する一般的方法
DE19856064C2 (de) 1998-12-04 2000-11-30 Invitek Gmbh Universelles Verfahren zur Isolierung von DNA aus beliebigen Ausgangsmaterialien
ES2315238T3 (es) 1999-07-19 2009-04-01 Biomerieux B.V. Metodo para mezclar particulas magneticas con un fluido.
GB0001450D0 (en) * 2000-01-21 2000-03-08 Genpoint As Cell isolation method
CN1230531C (zh) * 2002-12-09 2005-12-07 清华大学 从样品中分离细胞粒子的方法
DE102010031401A1 (de) 2010-07-15 2012-01-19 Aj Innuscreen Gmbh Verfahren zur Anreicherung von Bakterien, Viren sowie Zellen und zur nachfolgenden Nukleinsäureisolierung
EP3056565A1 (fr) 2015-02-13 2016-08-17 Karlsruher Institut für Technologie Immobilisation de cellules ou de particules de virus sur des structures protéiques au moyen d'une chambre microfluidique
DE102015211394B4 (de) 2015-06-19 2022-07-28 Ist Innuscreen Gmbh Vorrichtung und Verfahren zur Extraktion von Nukleinsäuren
DE102015211393A1 (de) 2015-06-19 2016-12-22 Aj Innuscreen Gmbh Vorrichtung und Verfahren zur automatisierten Extraktion von Nukleinsäuren
DE102015216558A1 (de) 2015-04-23 2016-10-27 Aj Innuscreen Gmbh Verfahren und testkit zur schnellen isolierung von nukleinsäuren mittels rauer oberflächen
CA2983619C (fr) 2015-04-23 2022-08-30 Aj Innuscreen Gmbh Procede et kit d'essai pour l'isolation rapide d'acides nucleiques au moyen de surfaces rugueuses
KR102190922B1 (ko) 2015-09-01 2020-12-14 삼성전자주식회사 핵산 분리 방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023247628A1 (fr) 2022-06-21 2023-12-28 Ist Innuscreen Gmbh Procédé et kit de préparation manuelle et automatisée d'échantillons de séquençages à lecture longue

Also Published As

Publication number Publication date
WO2018167138A1 (fr) 2018-09-20
DE102017204267A1 (de) 2018-09-20
US11702648B2 (en) 2023-07-18
DE102017204267B4 (de) 2021-05-27
CN110945124A (zh) 2020-03-31
US20200255820A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
DE102017204267B4 (de) Verfahren zur anreicherung von zellen aus einer probe und der nachfolgenden nukleinsäureisolierung aus diesen zellen
DE69817484T2 (de) Verfahren zur isolierung bestimmter biologischer stoffe mittels magnetischer silika-partikel
EP1960520B1 (fr) Procédé d'isolation d'acides nucléiques à partir de matériaux de départ quelconques
EP3286325B1 (fr) Procédé et kit d'essai pour l'isolation rapide d'acides nucléiques au moyen de surfaces rugueuses
DE112010001766B4 (de) Verfahren zur isolierung hochreiner rna mittels paramagnetischen mikro- und nanopartikeln
WO1999040098A1 (fr) Procede pour isoler et purifier des acides nucleiques
WO2007051859A1 (fr) Procede et dispositif pour isoler et nettoyer automatiquement des acides nucleiques a partir de matieres premieres eventuellement complexes
EP1560926B1 (fr) Nouvelles formulations de tampons pour isoler, purifier et recuperer des acides nucleiques a chaine longue et a chaine courte
DE102016214909B4 (de) Tragbare Nukleinsäure-Extraktionsvorrichtung und Verfahren zu deren Verwendung
EP1771242B1 (fr) Procede permettant d'isoler efficacement des acides nucleiques
WO2012007581A1 (fr) Procédé pour enrichir des bactéries, des virus et des cellules, et pour isoler ensuite leurs acides nucléiques
DE10253351B4 (de) Neuartige Pufferfomulierungen zur Isolierung, Reinigung und Rückgewinnung lang- und kurzkettiger Nukleinsäuren
DE102006031764A1 (de) Verfahren zur parallelen Isolierung doppel- und einzelsträngiger Nukleinsäuren sowie zur selektiven Entfernung doppelsträngiger Nukleinsäuren aus einem Gemisch von doppel- und einzelsträngigen Nukleinsäuren
WO2001046686A9 (fr) Materiau chromatographique et procedes d'utilisation d'un tel materiau
DE102015216558A1 (de) Verfahren und testkit zur schnellen isolierung von nukleinsäuren mittels rauer oberflächen
DE102015211394B4 (de) Vorrichtung und Verfahren zur Extraktion von Nukleinsäuren
DE19858447A1 (de) Verfahren zur Isolierung von kurz- und langkettigen Nukleinsäuren
EP1709172B1 (fr) Methode et kit d'isolation d'arn
DE102015211393A1 (de) Vorrichtung und Verfahren zur automatisierten Extraktion von Nukleinsäuren
WO2012007582A1 (fr) Procédé de préparation rapide de constituants à partir d'échantillons biologiques

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191014

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210915